Thus, dual-targeted NIR-PIT is a reasonable treatment for esophageal cancer patients with poor prognosis expressing both EGFR and FAP, as it can simultaneously attack both cancer cells and stroma and break the relationship. This evidence concerns the gene EGFR and cancer.